1008P cytoTIL15: A novel TIL therapy for melanoma with superior potency and enhanced persistence without IL2 to improve safety & efficacy and expand patient eligibility

• DOI: 10.1016/j.annonc.2021.08.1392
• Publication Date: 2021-09-21T15:05:07Z
• Authors: M. Khattar; R. Burga; K. Pedro; C. Foley; S. Lajoie; A.V. Ocando; J. Tremblay; D. Thornton; S. Tam; F. Nabulsi; C. Vallaster; S. Saha; G. Wilmes; G. Helmlinger; J. Tchaicha; D. Sethi; M. Ols; G. Vanasse; S. Subramanian; J. ter Meulen
• Keywords: Persistence (discontinuity)